{
  "thread": {
    "uuid": "573d858ad2ffc312e958589ba7c0c6662f34b352",
    "url": "https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26",
    "site_full": "www.marketbeat.com",
    "site": "marketbeat.com",
    "site_section": "https://www.marketbeat.com/instant-alerts",
    "site_categories": [
      "investing",
      "financial_news",
      "finance",
      "stocks"
    ],
    "section_title": "\r\n\tStock Market Alerts | MarketBeat\r\n",
    "site_title": null,
    "title": "Vir Biotechnology (NASDAQ:VIR) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS",
    "title_full": "Vir Biotechnology (NASDAQ:VIR) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS",
    "published": "2025-02-28T00:36:00.000+02:00",
    "replies_count": 0,
    "participants_count": 1,
    "site_type": "news",
    "country": "US",
    "main_image": "https://www.marketbeat.com/logos/vir-biotechnology-inc-logo-1200x675.jpg?v=20240524073518",
    "performance_score": 0,
    "domain_rank": 7907,
    "domain_rank_updated": "2025-02-24T23:00:00.000+02:00",
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "573d858ad2ffc312e958589ba7c0c6662f34b352",
  "url": "https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26",
  "ord_in_thread": 0,
  "parent_url": null,
  "author": "MarketBeat",
  "published": "2025-02-28T00:36:00.000+02:00",
  "title": "Vir Biotechnology (NASDAQ:VIR) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS",
  "text": "Vir Biotechnology (NASDAQ:VIR) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS Written by MarketBeat February 27, 2025 Share Link copied to clipboard. Vir Biotechnology ( NASDAQ:VIR - Get Free Report ) released its earnings results on Wednesday. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09, Zacks reports. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. Get Vir Biotechnology alerts: Sign Up Vir Biotechnology Stock Up 1.1 % From laggards to leaders: Small caps on the rise\nShares of NASDAQ VIR traded up $0.10 during trading on Wednesday, hitting $9.20. 843,868 shares of the company traded hands, compared to its average volume of 2,533,510. The firm has a market capitalization of $1.27 billion, a P/E ratio of -2.35 and a beta of 0.63. The company has a 50-day moving average price of $9.38 and a 200-day moving average price of $8.49. Vir Biotechnology has a 1 year low of $6.56 and a 1 year high of $14.45. Analyst Upgrades and Downgrades\nA number of research firms have recently weighed in on VIR. JPMorgan Chase & Co. boosted their price objective on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a \"neutral\" rating in a research report on Thursday, January 9th. Leerink Partners increased their price target on Vir Biotechnology from $18.00 to $20.00 and gave the stock an \"outperform\" rating in a research note on Monday, January 13th. Needham & Company LLC reaffirmed a \"buy\" rating and issued a $19.00 price objective on shares of Vir Biotechnology in a research report on Wednesday, November 20th. HC Wainwright reiterated a \"buy\" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research note on Friday, January 31st. Finally, Barclays decreased their price target on Vir Biotechnology from $28.00 to $26.00 and set an \"overweight\" rating on the stock in a research note on Monday, November 4th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of \"Moderate Buy\" and an average price target of $34.83.\nVirios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal Read Our Latest Stock Report on VIR Insider Buying and Selling\nIn other news, Director Vicki L. Sato sold 10,960 shares of the stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now owns 1,312,391 shares in the company, valued at approximately $16,431,135.32. This trade represents a 0.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link . Also, Director George A. Scangos sold 10,964 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the sale, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. The trade was a 1.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here . In the last ninety days, insiders have sold 23,562 shares of company stock valued at $259,693. 15.60% of the stock is currently owned by company insiders. About Vir Biotechnology ( Get Free Report ) Wall Street Sees Vir Biotechnology Bouncing Hard\nVir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). Read More\nThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.\nShould You Invest $1,000 in Vir Biotechnology Right Now? Before you consider Vir Biotechnology, you'll want to hear this.\nMarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.\nWhile Vir Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.\nView The Five Stocks Here\n7 Top Nuclear Stocks To Buy Now Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.\nGet This Free Report Like this article? Share it with a colleague. Link copied to clipboard.",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "english",
  "sentiment": "positive",
  "categories": [
    "Economy, Business and Finance",
    "Health",
    "Science and Technology"
  ],
  "topics": [
    "Economy, Business and Finance->business and market analysis",
    "Economy, Business and Finance->business reporting and performance",
    "Economy, Business and Finance->financial service",
    "Health->health organisation",
    "Health->medical profession",
    "Health->health insurance",
    "Science and Technology->biomedical science",
    "Science and Technology->medical research"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": false,
  "webz_reporter": false,
  "external_links": [
    "http://www.zacks.com/",
    "https://www.americanconsumernews.net/scripts/standalone/viewcount.ashx?type=e&id=748093&domain=marketbeat.com&referrer=",
    "http://www.sec.gov/Archives/edgar/data/1202102/000162828025006516/xslF345X05/wk-form4_1740010306.xml",
    "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "http://www.sec.gov/Archives/edgar/data/1197020/000162828025000994/xslF345X05/wk-form4_1736384620.xml",
    "https://twitter.com/intent/tweet?text=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20%24VIR%20%23VIR%20https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://www.american",
    "https://www.facebook.com/sharer/sharer.php?u=https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://www.linkedin.com/cws/share?mini=true&url=https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://twitter.com/intent/tweet?text=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://www.linkedin.com/cws/share?mini=true&url=https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26",
    "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20https://marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://www.facebook.com/sharer/sharer.php?u=https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26",
    "https://american",
    "http://www.zacks.com",
    "https://twitter.com/intent/tweet?text=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20%24VIR%20%23VIR%20https://marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://americanconsumernews.net/scripts/standalone/viewcount.ashx?type=e&id=748093&domain=marketbeat.com&referrer=",
    "https://facebook.com/sharer/sharer.php?u=https://marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://twitter.com/intent/tweet?text=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26",
    "http://sec.gov/Archives/edgar/data/1202102/000162828025006516/xslF345X05/wk-form4_1740010306.xml",
    "https://linkedin.com/cws/share?mini=true&url=https://marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://www.linkedin.com/cws/share",
    "https://twitter.com/intent/tweet?text=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20%24VIR%20%23VIR%20https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26",
    "https://api.stocktwits.com/widgets/share",
    "https://www.americanconsumernews.net/scripts/standalone/viewcount.ashx",
    "http://zacks.com/",
    "https://www.facebook.com/sharer/sharer.php",
    "https://api.stocktwits.com/widgets/share?via=MarketBeat&body=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20https://www.marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26",
    "https://twitter.com/intent/tweet?text=Vir+Biotechnology+(NASDAQ%3aVIR)+Issues+Quarterly++Earnings+Results%2c+Beats+Estimates+By+%240.09+EPS%20https://marketbeat.com/instant-alerts/vir-biotechnology-nasdaqvir-issues-quarterly-earnings-results-beats-estimates-by-009-eps-2025-02-26/",
    "https://twitter.com/intent/tweet",
    "http://sec.gov/Archives/edgar/data/1197020/000162828025000994/xslF345X05/wk-form4_1736384620.xml"
  ],
  "external_images": [],
  "entities": {
    "persons": [],
    "organizations": [],
    "locations": []
  },
  "syndication": {
    "syndicated": false,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": null,
  "rating": null,
  "crawled": "2025-02-28T00:41:43.932+02:00",
  "updated": "2025-02-28T00:41:43.932+02:00"
}